The report by Gardner et al. 1 analyzes International Blood and Marrow Transplant Registry (IBMTR) data regarding myeloablative therapy with autologous stem cell rescue for Ewing sarcoma. The limitations of this report, which is based on an observational database, are reviewed in the Discussion. Clarifications about some of the comparisons in the Discussion are important because this article will likely influence clinical practice.
The report by Gardner et al. 1 analyzes International Blood and Marrow Transplant Registry (IBMTR) data regarding myeloablative therapy with autologous stem cell rescue for Ewing sarcoma. The limitations of this report, which is based on an observational database, are reviewed in the Discussion. Clarifications about some of the comparisons in the Discussion are important because this article will likely influence clinical practice.
For example, a comparison of the outcome for patients with localized disease at diagnosis is made. The comparison is between the IBMTR results for megatherapy and the results of a study that incorporated etoposide and ifosfamide. 2 The latter study was not limited to high-risk patients, so it is possible that there was a significant difference in risk factors such as tumor size and location. Because the addition of etoposide and ifosfamide was shown to improve outcome, the induction therapy used is important for this comparison and it is not known for the IBMTR patients.
The study of chemotherapy including etoposide and ifosfamide was also reported for patients with metastatic disease. 3 A comparison between the IBMTR data and these data is made in the discussion. The 5-year PFS for the IBMTR data was 34%, and the authors compare this to the 5-year PFS of 29% with chemotherapy. However, the value used by the authors is the overall survival, and the 8-year EFS was only 20%. 3 The follow-up is longer in the chemotherapy study, but the EFS curve did not change much from 5 to 8 years.
A prospective study that used etoposide and ifosfamide in induction and consolidation with myeloablative therapy with busulfan and melphalan was reported by Oberlin et al. 4 Ninety-seven newly diagnosed patients with metastatic Ewing sarcoma were enrolled and the 5-year EFS was 37%. The 5-year EFS for lung-only metastases was 52%, and this compares favorably with the 34% 8-year EFS reported in 32 patients with lung-only metastases reported with chemotherapy. 3 Data regarding the site of metastases are not given in the IBMTR report, and this could be important, as patients with other sites of disease fared much worse in the report by Oberlin et al.
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In conclusion, valid comparisons between chemotherapy and myeloablative therapy can be made only on the basis of a randomized trial. We share the desire with Gardner et al. to see the results of the randomized Euro EWING 99 study. Interestingly, the possible 10-20% advantage in PFS associated with megatherapy suggested above is very similar to that reported for high-risk neuroblastoma. 5 AL Gilman and J Oesterheld Department of Pediatrics, Levine Children's Hospital, Charlotte, NC, USA E-mail: andrew.gilman@carolinashealthcare.org
